| Literature DB >> 34794409 |
Li Chen1, Liang Lin1, Ling Li1, Zuolian Xie1, Haixin He1, Cuibo Lin1, Jian Chen1, An Lin2.
Abstract
BACKGROUND: The study aims to evaluate the clinical features and management of postoperative lymphatic leakage (PLL) in patients with cervical cancer who received pelvic lymphadenectomy.Entities:
Keywords: Cervical cancer; Lymph node dissection; Lymphatic leakage
Mesh:
Year: 2021 PMID: 34794409 PMCID: PMC8603468 DOI: 10.1186/s12885-021-08984-1
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Assignment of variables in the multivariate logistic regression analysis
| Value | Assignment in multivariate analysis | |
|---|---|---|
| Preoperative albumin (g/L) | ≥35 | 1 |
| < 35 and ≥ 30 | 2 | |
| < 30 | 3 | |
| Postoperative hemoglobin (g/L) | ≥110 | 1 |
| < 110 and ≥ 90 | 2 | |
| < 90 | 3 | |
| Postoperative albumin(g/L) | ≥35 | 1 |
| < 35 and ≥ 30 | 2 | |
| < 30 | 3 | |
| Decrease in hemoglobin (g/L) | < 10 | 1 |
| < 20 and ≥ 10 | 2 | |
| < 30 and ≥ 20 | 3 | |
| ≥30 | 4 | |
| Decrease in albumin (g/L) | < 5 | 1 |
| < 10 and ≥ 5 | 2 | |
| < 15 and ≥ 10 | 3 | |
| ≥15 | 4 | |
| Number of lymph nodes resected | <25 | 1 |
| <35 and ≥ 25 | 2 | |
| ≥35 | 3 |
Clinical characteristics of the study participants
| Characteristic | Case group | Control group | |
|---|---|---|---|
| Age | 52.86 ± 8.56 | 51.59 ± 7.81 | 0.386 |
| Height (cm) | 157.78 ± 4.23 | 158.29 ± 4.17 | 0.499 |
| Weight (kg) | 58.25 ± 4.78 | 57.37 ± 5.86 | 0.352 |
| Body mass index (kg/m2) | 23.39 ± 1.67 | 22.85 ± 1.74 | 0.078 |
| Comorbid diabetes mellitus | 0.219 | ||
| Yes | 19 (30.2%) | 13 (20.6%) | |
| No | 44 (69.8%) | 50 (79.4%) | |
| FIGO Stage | 0.859 | ||
| I | 32 (50.8%) | 31 (49.2%) | |
| II | 31 (49.2%) | 32 (50.8%) | |
| Histologic type | 0.338 | ||
| Squamous cell carcinoma | 45 (71.4%) | 38 (60.3%) | |
| Adenocarcinoma | 12 (19.0%) | 19 (30.2%) | |
| Other | 6 (9.5%) | 6 (9.5%) | |
| Number of NACT cycles | 0.021* | ||
| 0 | 26 (41.3%) | 37 (58.7%) | |
| 1 | 12 (19.0%) | 13 (20.6%) | |
| 2 | 25 (39.7%) | 13 (20.6%) | |
| Neoadjuvant radiotherapy | 0.051 | ||
| Yes | 37 (58.7%) | 26 (41.3%) | |
| No | 26 (41.3%) | 37 (58.7%) | |
| Surgical method | 0.672 | ||
| Laparoscopy | 24 (38.1%) | 22 (34.9%) | |
| Laparotomy | 39 (61.9%) | 41 (65.1%) | |
| Duration of surgery (h) | 3.2 ± 1.0 | 2.9 ± 0.9 | 0.983 |
| Intraoperative bleeding volume (mL) | 253 ± 75 | 256 ± 71 | 0.770 |
| Number of lymph nodes resected | 37 ± 7 | 34 ± 8 | 0.008* |
| Lymph node metastasis | 0.052 | ||
| Yes | 6 (9.5%) | 1 (1.6%) | |
| No | 57 (90.5%) | 62 (98.4%) | |
| Postoperative pelvic infection | 0.045* | ||
| Yes | 22 (34.9%) | 12 (19.0%) | |
| No | 41 (65.1%) | 51 (81.0%) | |
| Preoperative hemoglobin level (g/L) | 137.08 ± 4.15 | 136.52 ± 5.16 | 0.506 |
| Preoperative albumin level (g/L) | 39.68 ± 4.15 | 38.10 ± 5.16 | 0.000* |
| Postoperative hemoglobin level (g/L) | 97.44 ± 8.44 | 101.40 ± 8.56 | 0.010* |
| Postoperative albumin level (g/L) | 30.39 ± 2.14 | 31.40 ± 2.83 | 0.025* |
| Decrease in hemoglobin level (g/L)§ | 39.63 ± 8.83 | 35.13 ± 7.44 | 0.002* |
| Decrease in albumin level (g/L)§ | 9.29 ± 2.15 | 6.70 ± 2.34 | 0.000* |
Data are presented as mean ± standard deviation or n (%). NACT: neoadjuvant chemotherapy. § Preoperative level minus postoperative level. * P < 0.05
Fig. 1Flowchart of enrolment and analysis process
Multivariate analysis of factors associated with postoperative lymphatic leakage
| Factor | OR | 95% CI | ||
|---|---|---|---|---|
| Number of NACT cycles | 0 | – | ||
| 1 | 2.679 | 0.876–8.197 | 0.084 | |
| 2 | 3.283 | 1.289–8.360 | 0.013* | |
| Decrease in hemoglobin level (g/L) | < 10 | – | ||
| ≥10 and < 20 | 4.973 | 0.810–6.542 | 0.083 | |
| ≥20 and < 30 | 6.175 | 1.033–10.919 | 0.046* | |
| ≥30 | 8.467 | 1.248–17.426 | 0.029* | |
| Postoperative albumin level (g/L) | ≥35 | – | ||
| ≥30 and < 35 | 2.552 | 1.112–5.857 | 0.027* | |
| < 30 | 5.517 | 2.047–18.148 | 0.012* | |
| Number of lymph nodes resected | <25 | – | ||
| <35 and ≥ 25 | 2.561 | 0.172–8.008 | 0.405 | |
| ≥35 | 3.049 | 0.221–12.011 | 0.081 | |
NACT: neoadjuvant chemotherapy; OR: odds ratio; 95%CI: 95% confidence interval
*P < 0.05